Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07601074 · ClinicalTrials.gov registry record · Phase 2
A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV)
A Phase 2 study, sponsored by Daré Bioscience.
- Not yet
- Registry status
- Phase 2
- Development phase
- 118
- Enrollment target
NCT07601074 is a Phase 2 study that has not yet begun recruiting, run by Daré Bioscience. The registered enrollment target is 118 participants.
The verdict
NCT07601074, a Phase 2 study, has not yet begun recruiting, sponsored by Daré Bioscience.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 118 participants
- Enrollment target
Study Summary
The goal of this clinical study is to learn if DARE-HPV can treat persistent high-risk human papillomavirus (hrHPV). The primary outcome will be if the genital infection clears following treatment in 30, 60 or 90 days. The study will look at two different doses of DARE-HPV and two different treatment durations of 14 and 21 days compared to a placebo group or 14 or 21 days of treatment.
Interventions
- DRUG Lopinavir / ritonavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2026-06 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07601074
The ClinicalTrials.gov registry entry for NCT07601074 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 118 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daré Bioscience, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lopinavir / ritonavir is the first listed.
NCT07601074 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07601074 about?
NCT07601074 is a clinical study titled "A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV)". The goal of this clinical study is to learn if DARE-HPV can treat persistent high-risk human papillomavirus (hrHPV). The primary outcome will be if the genital infection clears following treatment in 30, 60 or 90 days. The study will look at two different doses of DARE-HPV and two different treatme...
What is the current status of trial NCT07601074?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 118 participants. The study started on 2026-06. Estimated completion is 2027-12.
What interventions are being tested in trial NCT07601074?
The interventions under investigation include: Lopinavir / ritonavir (DRUG).
Who is sponsoring clinical trial NCT07601074?
This trial is sponsored by Daré Bioscience, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.